clinical trial · NCT05462106
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Amyloid PlaqueBeta-AmyloidDSADProdromal Alzheimer's DiseaseAlzheimer's DiseasePlaceboACI-24.060 at Dose AACI-24.060 at Dose BACI-24.060 at Dose CACI-24.060 at Dose DPlaceboACI-24.060 at Dose AACI-24.060 at Dose B
brief summary
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
started
Jun 21, 2022
primary completion
Jun 1, 2026
completion
Jun 1, 2026
last updated
Dec 15, 2025
detailed description
This phase 1b/2 study will be in 2 parts. Study Part 1 will involve subjects with prodromal Alzheimer's disease. Study Part 2 will involve subjects with Down syndrome.
official title
A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol